Kyra Y L Chua1, Sara Vogrin2, Susan Bury1,3, Abby Douglas4, Natasha E Holmes1, Nixon Tan1, Natasha K Brusco5,6, Rebecca Hall1, Belinda Lambros4, Jacinta Lean4, Wendy Stevenson1, Misha Devchand1,3, Kent Garrett3, Karin Thursky4,7,8, M Lindsay Grayson1,9, Monica A Slavin4,8, Elizabeth J Phillips10,11, Jason A Trubiano1,4,9. 1. Department of Infectious Diseases and Centre for Antibiotic Allergy and Research, Austin Health, Heidelberg, Australia. 2. Department of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Australia. 3. Department of Pharmacy, Austin Health, Heidelberg, Australia. 4. Department of Infectious Diseases and the National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Australia. 5. Alpha Crucis Group, Health Economics, Langwarrin, Australia. 6. Rehabilitation, Ageing and Independent Living Research Centre, Monash University, Frankston, Australia. 7. National Centre for Antimicrobial Stewardship, Royal Melbourne Hospital, Melbourne, Australia. 8. Department of Oncology, Sir Peter MacCallum Cancer Centre, University of Melbourne, Parkville, Australia. 9. Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Australia. 10. Department of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 11. Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia.
Abstract
BACKGROUND: Penicillin allergies are associated with inferior patient and antimicrobial stewardship outcomes. We implemented a whole-of-hospital program to assess the efficacy of inpatient delabeling for low-risk penicillin allergies in hospitalized inpatients. METHODS: Patients ≥ 18 years of age with a low-risk penicillin allergy were offered a single-dose oral penicillin challenge or direct label removal based on history (direct delabeling). The primary endpoint was the proportion of patients delabeled. Key secondary endpoints were antibiotic utilization pre- (index admission) and post-delabeling (index admission and 90 days). RESULTS: Between 21 January 2019 and 31 August 2019, we assessed 1791 patients reporting 2315 antibiotic allergies, 1225 with a penicillin allergy. Three hundred fifty-five patients were delabeled: 161 by direct delabeling and 194 via oral penicillin challenge. Ninety-seven percent (194/200) of patients were negative upon oral penicillin challenge. In the delabeled patients, we observed an increase in narrow-spectrum penicillin usage (adjusted odds ratio [OR], 10.51 [95% confidence interval {CI}, 5.39-20.48]), improved appropriate antibiotic prescribing (adjusted OR, 2.13 [95% CI, 1.45-3.13]), and a reduction in restricted antibiotic usage (adjusted OR, 0.38 [95% CI, .27-.54]). In the propensity score analysis, there was an increase in narrow-spectrum penicillins (OR, 10.89 [95% CI, 5.09-23.31]) and β-lactam/β-lactamase inhibitors (OR, 6.68 [95% CI, 3.94-11.35]) and a reduction in restricted antibiotic use (OR, 0.52 [95% CI, .36-.74]) and inappropriate prescriptions (relative risk ratio, 0.43 [95% CI, .26-.72]) in the delabeled group compared with the group who retained their allergy label. CONCLUSIONS: This health services program using a combination of direct delabeling and oral penicillin challenge resulted in significant impacts on the use of preferred antibiotics and appropriate prescribing.
BACKGROUND:Penicillin allergies are associated with inferior patient and antimicrobial stewardship outcomes. We implemented a whole-of-hospital program to assess the efficacy of inpatient delabeling for low-risk penicillin allergies in hospitalized inpatients. METHODS:Patients ≥ 18 years of age with a low-risk penicillinallergy were offered a single-dose oral penicillin challenge or direct label removal based on history (direct delabeling). The primary endpoint was the proportion of patients delabeled. Key secondary endpoints were antibiotic utilization pre- (index admission) and post-delabeling (index admission and 90 days). RESULTS: Between 21 January 2019 and 31 August 2019, we assessed 1791 patients reporting 2315 antibiotic allergies, 1225 with a penicillinallergy. Three hundred fifty-five patients were delabeled: 161 by direct delabeling and 194 via oral penicillin challenge. Ninety-seven percent (194/200) of patients were negative upon oral penicillin challenge. In the delabeled patients, we observed an increase in narrow-spectrum penicillin usage (adjusted odds ratio [OR], 10.51 [95% confidence interval {CI}, 5.39-20.48]), improved appropriate antibiotic prescribing (adjusted OR, 2.13 [95% CI, 1.45-3.13]), and a reduction in restricted antibiotic usage (adjusted OR, 0.38 [95% CI, .27-.54]). In the propensity score analysis, there was an increase in narrow-spectrum penicillins (OR, 10.89 [95% CI, 5.09-23.31]) and β-lactam/β-lactamase inhibitors (OR, 6.68 [95% CI, 3.94-11.35]) and a reduction in restricted antibiotic use (OR, 0.52 [95% CI, .36-.74]) and inappropriate prescriptions (relative risk ratio, 0.43 [95% CI, .26-.72]) in the delabeled group compared with the group who retained their allergy label. CONCLUSIONS: This health services program using a combination of direct delabeling and oral penicillin challenge resulted in significant impacts on the use of preferred antibiotics and appropriate prescribing.
Authors: Jason A Trubiano; Rekha Pai Mangalore; Yi-Wei Baey; Duy Le; Linda V Graudins; Patrick G P Charles; Douglas F Johnson; Ar Kar Aung Journal: Med J Aust Date: 2016-04-18 Impact factor: 7.738
Authors: Jason A Trubiano; Nada Marhoon; Sara Vogrin; Kyra Y L Chua; Natasha E Holmes Journal: Antimicrob Agents Chemother Date: 2020-11-17 Impact factor: 5.191
Authors: Rebecca E Berger; Harjot K Singh; Angela S Loo; Victoria Cooley; Snezana Nena Osorio; Jennifer I Lee; Matthew S Simon Journal: Jt Comm J Qual Patient Saf Date: 2021-12-09
Authors: Elizabeth W Covington; Spencer H Durham; Christopher M Bland; P Brandon Bookstaver; Elias B Chahine; Jonathan C Cho; Fernando Diggs; Bruce M Jones; Jeffrey A Kyle; Kayla R Stover; Jamie L Wagner; Peter J Hughes Journal: J Pharm Technol Date: 2021-12-21
Authors: Martijn Sijbom; Karolina K Braun; Frederike L Büchner; Leti van Bodegom-Vos; Bart J C Hendriks; Mark G J de Boer; Mattijs E Numans; Merel M C Lambregts Journal: PLoS One Date: 2022-04-07 Impact factor: 3.240
Authors: Clark D Russell; Cameron J Fairfield; Thomas M Drake; Lance Turtle; R Andrew Seaton; Dan G Wootton; Louise Sigfrid; Ewen M Harrison; Annemarie B Docherty; Thushan I de Silva; Conor Egan; Riinu Pius; Hayley E Hardwick; Laura Merson; Michelle Girvan; Jake Dunning; Jonathan S Nguyen-Van-Tam; Peter J M Openshaw; J Kenneth Baillie; Malcolm G Semple; Antonia Ho Journal: Lancet Microbe Date: 2021-06-02